Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was issued on November 5, 2021. The report details positive Phase III efficacy and safety data for daprodustat, an investigational oral treatment for anaemia due to chronic kidney disease (CKD). The data was presented at the American Society of Nephrology's Kidney Week 2021 and published in the New England Journal of Medicine.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical trial update rather than a financial earnings report.
Material Changes and Clinical Results
The filing reports significant clinical milestones for the ASCEND programme, which enrolled over 8,000 patients across five Phase III studies:
- Efficacy: Daprodustat improved or maintained haemoglobin (Hb) within target levels (10-11.5 g/dL) in both non-dialysis (ASCEND-ND) and dialysis (ASCEND-D) populations.
- Safety: The drug demonstrated non-inferiority regarding Major Adverse Cardiovascular Events (MACE) compared to the standard of care (erythropoietin stimulating agents).
- ASCEND-ND Hazard Ratio: 1.03 (95% CI, 0.89 to 1.19).
- ASCEND-D Hazard Ratio: 0.93 (95% CI, 0.81-1.07).
- Adverse Events: The most commonly reported events included hypertension, diarrhoea, dialysis hypotension, peripheral oedema, and urinary tract infection.
- Dosing: Additional trials supported both once-daily and three-times weekly dosing regimens.
Outlook, Management Commentary, and Risks
Management Commentary: Dr. Hal Barron, Chief Scientific Officer, stated that daprodustat has the potential to transform the treatment landscape for the estimated 1-in-7 CKD patients suffering from anaemia. The drug is based on Nobel Prize-winning science regarding cellular oxygen sensing.
Regulatory Outlook: Daprodustat is currently approved in Japan as Duvroq. The Phase III results will support regulatory filings with health authorities worldwide for markets where it is not yet approved.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the 2020 Form 20-F, Q3 results, and the ongoing impacts of the COVID-19 pandemic.
Key Facts for Investor Verification
- Verify the timeline for regulatory submissions in the US (FDA) and Europe (EMA) following the publication of ASCEND-ND and ASCEND-D results.
- Confirm the commercial potential of daprodustat given its current approval status only in Japan.
- Monitor the long-term safety data, specifically regarding cardiovascular events, as the drug is compared against the current standard of care (ESA).
- Review the impact of the ASCEND programme on GSK's overall R&D pipeline valuation and future revenue projections for the renal disease portfolio.